VERX Stock Recent News

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator treatment for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive muta.

Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals. The company's 2024 performance was solid, with TRIKAFTA/KAFTRIO generating >$10bn revenues, and 2025 guidance suggesting continued growth despite some challenges. Vertex's diversification efforts include the approval of pain therapy JOURNAVX and gene therapy Casgevy, with potential multi-billion-dollar revenue contributions from these and other pipeline drugs.

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor for the treatment of people with cystic fibrosis (CF) aged 2 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “We.

Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to detail his many portfolio moves.

Vertex, Inc. (NASDAQ:VERX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Joe Crivelli – Vice President of Investor Relations David DeStefano – President and Chief Executive Officer John Schwab – Chief Financial Officer Conference Call Participants Rob Oliver – Baird Chris Quintero – Morgan Stanley Joshua Reilly – Needham Samad Samana – Jefferies Steve Enders – Citi Daniel Jester – BMO Capital Markets Jacob Roberge – William Blair Alex Sklar – Raymond James Patrick Walravens – Citizens William Jellison – D.A. Davidson Adam Hotchkiss – Goldman Sachs Operator Good morning and welcome to the Vertex Incorporated Fourth Quarter 2024 Earnings Conference Call.

The headline numbers for Vertex (VERX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.13 per share a year ago.

KING OF PRUSSIA, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its fourth quarter and full year ended December 31, 2024.

VERX's fourth-quarter 2024 performance is likely to have benefited from the growing adoption of cloud-based tax automation solutions.

Get a deeper insight into the potential performance of Vertex (VERX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.